EUVIMEDEUVIMED entdecken
Crossref

Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A

Katsuyuki Sakanaka iD, Ken Kato iD, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko iD, Takeshi Kajiwara, Yasuhiro Tsubosa, Keiko Minashi, Tetsuya Abe iD, Takashi Kojima, Hiroki Hara, Hirofumi Kawakubo iD und 8 weitere

Diseases of the Esophagus · 02.07.2026 · 39 (4)

DOI: 10.1093/dote/doag072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 13.07.2026. Verfasst von Katsuyuki Sakanaka und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoembryonic Antigen, Esophageal Neoplasms, Serpins, Chemoradiotherapy. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Squamous cell carcinoma antigen (SCC-Ag) and carcinoembryonic antigen (CEA) are routinely monitored after definitive chemoradiotherapy (dCRT) for esophageal squamous cell carcinoma (ESCC) in Japan, but their clinical significance remains unclear.

Methods

We analyzed data from patients with resectable ESCC treated with dCRT in the JCOG0502 and JCOG0909 trials, who underwent intensive protocolized surveillance with computed tomography (CT), esophagogastroduodenoscopy (EGD), SCC-Ag, and CEA. Tumor marker positivity was defined as exceeding the cut-off value at least once, at two consecutive measurements, or at three consecutive measurements during follow-up. Sensitivity and specificity were calculated for SCC-Ag and CEA at 0.1-ng/mL increments to determine whether any cut-off met the predefined performance criteria (sensitivity ≥60% and specificity ≥70%).

Results

This study included 239 patients (stage I/II/III = 147/58/34 [UICC 6th edition]), among whom 38% (91/239) experienced disease progression or recurrence. The median baseline SCC-Ag and CEA levels were 1.0 ng/mL (interquartile range [IQR], 0.8–1.5) and 2.3 ng/mL (IQR, 1.6–3.6), respectively, with a median of 16 measurements each (IQR, 8–19 for SCC-Ag; 8–20 for CEA). The highest specificities with sensitivity ≥60% were 19.6% for SCC-Ag (cut-off, 1.5 ng/mL) and 20.3% for CEA (cut-off, 2.2 ng/mL), but neither met the predefined criteria.

Conclusions

In this pooled cohort of patients with resectable ESCC who underwent dCRT and intensive protocolized CT and EGD surveillance, routine SCC-Ag and CEA monitoring showed limited incremental diagnostic value. The relevance of these findings to higher-risk cohorts and less intensive surveillance settings warrants further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoembryonic AntigenEsophageal NeoplasmsSerpinsChemoradiotherapyAntigens, NeoplasmBiomarkers, TumorCarcinoma, Squamous CellHumansMiddle AgedEsophageal Squamous Cell CarcinomaMaleFemaleAgedSensitivity and SpecificityJapanTomography, X-Ray ComputedDisease ProgressionNeoplasm Recurrence, LocalEndoscopy, Digestive System

Stichwörter der Autor:innen

chemoradiotherapyesophageal squamous cell carcinomatumor marker

Substanzen

Carcinoembryonic Antigensquamous cell carcinoma-related antigenSerpinsAntigens, NeoplasmBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • National Cancer Center Hospital, Japan Clinical Oncology Group Data Center/Operations Office, Tokyo, Japan.
  • Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.

ORCID-Profile: Katsuyuki Sakanaka, Ken Kato, Hiroyuki Daiko, Tetsuya Abe, Hirofumi Kawakubo, Shigeru Tsunoda, Yuichiro Doki, Yasue Kimura, Keita Sasaki, Hiroya Takeuchi, Yuko Kitagawa

Zitieren

APA

Sakanaka, K., Kato, K., Machida, R., Ito, Y., Daiko, H., Kajiwara, T., Tsubosa, Y., Minashi, K., Abe, T., Kojima, T., Hara, H., Kawakubo, H., Tsunoda, S., Watanabe, M., Doki, Y., Nagatani, Y., Kimura, Y., Sasaki, K., Takeuchi, H., & Kitagawa, Y. (2026). Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A. Diseases of the Esophagus, 39(4). https://doi.org/10.1093/dote/doag072

Vancouver

Sakanaka K, Kato K, Machida R, Ito Y, Daiko H, Kajiwara T, et al. Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A. Diseases of the Esophagus. 2026;39(4). doi:10.1093/dote/doag072

BibTeX
@article{Sakanaka2026,
  author = {Sakanaka, Katsuyuki and Kato, Ken and Machida, Ryunosuke and Ito, Yoshinori and Daiko, Hiroyuki and Kajiwara, Takeshi and Tsubosa, Yasuhiro and Minashi, Keiko and Abe, Tetsuya and Kojima, Takashi and Hara, Hiroki and Kawakubo, Hirofumi and Tsunoda, Shigeru and Watanabe, Masaya and Doki, Yuichiro and Nagatani, Yoshiaki and Kimura, Yasue and Sasaki, Keita and Takeuchi, Hiroya and Kitagawa, Yuko},
  title = {Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A},
  journal = {Diseases of the Esophagus},
  year = {2026},
  volume = {39},
  number = {4},
  doi = {10.1093/dote/doag072}
}
Kostenlos starten →